Premium
Induction of systemic TNFα in Natalizumab‐treated multiple sclerosis
Author(s) -
Khademi M.,
Stol D.,
Olsson T.,
Wallström E.
Publication year - 2008
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.02037.x
Subject(s) - natalizumab , medicine , multiple sclerosis , tumor necrosis factor alpha , proinflammatory cytokine , peripheral blood mononuclear cell , immunology , interferon , inflammation , in vitro , biochemistry , chemistry
The mRNA expression of eight different cytokines in peripheral blood mononuclear cells in 19 individuals with multiple sclerosis was determined at baseline and after 6 months of open‐label treatment with natalizumab. Cellular expression of tumor necrosis factor α (TNFα) mRNA and number of cells secreting TNFα and interferon γ protein significantly increased over the 6 months. Kurtzke EDSS scores improved because of the resolution of relapses, but not fatigue severity scores. The observed increases in systemic proinflammatory cytokines by natalizumab treatment are discussed in relation to fatigue and systemic immunity.